China Liver Cancer Clinical Registry Cohort Database

Launched by ANHUI PROVINCIAL HOSPITAL · Jan 14, 2025

Keywords

ClinConnect Summary

The China Liver Cancer Clinical Registry Cohort Database is a study designed to gather important information about patients with liver cancer. The goal is to create a reliable database that helps researchers conduct high-quality studies to improve treatment and care for people with liver cancer. This trial is open to adults aged 18 and older, regardless of gender, who have been diagnosed with specific types of liver cancer either through imaging tests or surgery. Participants need to be willing to provide follow-up information and donate blood samples for research.

If you or a family member qualify for this study, you can expect to be part of a larger effort to understand liver cancer better. Participants will be asked to give their consent and may be required to provide health information and samples after surgery. However, individuals with certain severe health issues or those who are pregnant or breastfeeding cannot participate. This research aims to improve future treatments and outcomes for liver cancer patients, making it a significant opportunity for those affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years, no gender limit
• • Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
• • Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
• Exclusion Criteria:
• • Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
• • Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
• • Pregnant or breastfeeding women
• • Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected